The FDA has accepted Array BioPharma’s new drug application for binimetinib for treating patients with NRAS-mutant melanoma, according to a press release from the company.
Regulatory
NICE u-turn in favour of Amgen’s novel melanoma drug
The National Institute for Health and Care Excellence is now recommending NHS use of Amgen’s Imlygic to treat advanced melanoma that has spread and can’t be surgically removed.
Nivolumab/Ipilimumab Combo Approved in Europe for Advanced Melanoma
The European Commission has approved the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status, based on data from the CheckMate-069 and -067 studies.
FDA Approvals, New Biopsy Techniques Advance Head and Neck Melanoma Care
Advancements in biopsy techniques, as well as several recently approved new therapeutic agents, have made a significant difference in outcomes for patients with melanoma of the head and neck, says Carol Rossier Bradford, MD, a head and neck surgeon and professor of Otolaryngology at the University of Michigan Health System.